Bioadhesive monolayer film for the in vitro transdermal delivery of sumatriptan

Femenía-Font, A.; Padula, Cristina; Marra, Fabio; Balaguer-Fernández, C.; Merino, Virginia; López-Castellano, Alicia; Santi, Patrizia

doi:10.1002/jps.20638

Cited by 32 publications

(29 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total amount of sumatriptan that diffused from the patch was similar to that of sumatriptan solution, but with a higher rate of diffusion (flux) in the first 5 h. 13 The previously described patch consisted mainly of PVA (ϳ60% dry). 13 A subsequent study assessed a variety of other polymers for use in a transdermal sumatriptan system.…”

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 64%

“…Once it was established that sumatriptan could be delivered transdermally, additional in vitro experiments investigated the use of a bioadhesive patch 13 and various patch substrates 14 to assist with drug delivery. One of these studies examined the use of a patch made of polyvinyl alcohol (PVA), Plastoid E 35H (Rhom GmbH & Co. KG, Darmstadt, Germany), and sorbitol, with and without Transcutol (Gattefossé, Gennevilliers Cedex, France) or PEG600 to deliver sumatriptan.…”

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 99%

“…One of these studies examined the use of a patch made of polyvinyl alcohol (PVA), Plastoid E 35H (Rhom GmbH & Co. KG, Darmstadt, Germany), and sorbitol, with and without Transcutol (Gattefossé, Gennevilliers Cedex, France) or PEG600 to deliver sumatriptan. 13 The patches were placed on a portion of rabbit ear skin and diffusion was assessed via high-performance liquid chromatography similar to the previously described study. The total amount of sumatriptan that diffused from the patch was similar to that of sumatriptan solution, but with a higher rate of diffusion (flux) in the first 5 h. 13 The previously described patch consisted mainly of PVA (ϳ60% dry).…”

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 99%

“…13 The patches were placed on a portion of rabbit ear skin and diffusion was assessed via high-performance liquid chromatography similar to the previously described study. The total amount of sumatriptan that diffused from the patch was similar to that of sumatriptan solution, but with a higher rate of diffusion (flux) in the first 5 h. 13 The previously described patch consisted mainly of PVA (ϳ60% dry). 13 A subsequent study assessed a variety of other polymers for use in a transdermal sumatriptan system.…”

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 99%

See 3 more Smart Citations

Transdermal Delivery of Sumatriptan for the Treatment of Acute Migraine

Pierce

2010

Neurotherapeutics

View full text Add to dashboard Cite

Summary:Migraine is a common, multisymptom disorder that can severely impact the daily activities of migraineurs. Triptans (primarily sumatriptan) are the most commonly prescribed treatment for migraine and are considered a relatively safe and effective initial therapy. Unfortunately, current sumatriptan formulations (i.e., oral, nasal, subcutaneous) may be associated with limitations that can result in patients' delaying or avoiding treatment. For oral formulations, these limitations include difficulty in taking an oral medication due to the nausea and vomiting that often accompany migraine, and inconsistent absorption, whereas nasal and subcutaneous formulations may be associated with low bioavailability and an undesirable rate of adverse events, respectively. An alternative to current formulations is transdermal drug delivery, particularly iontophoresis. Transdermal delivery has several advantages over current formulations, including avoidance of the gastrointestinal tract, controlled and sustained delivery, and convenient administration. This article reviews the in vitro, in vivo, and preclinical data supporting the use of iontophoresis for the delivery of sumatriptan, as well as the recent clinical data for Zelrix (NuPathe Inc., Conshohocken, PA), an iontophoretic sumatriptan patch currently in phase III development for the treatment of migraine.

show abstract

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 64%

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 99%

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 99%

Section: Passive Transdermal Delivery Of Sumatriptan: In Vitro Model mentioning

confidence: 99%

See 2 more Smart Citations

Transdermal Delivery of Sumatriptan for the Treatment of Acute Migraine

Pierce

2010

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…To develop the formulations, diverse polymers were studied as a matricial support for the drug (Femenía-Font et al, 2006a;Balaguer-Fernández et al, 2007). In the first approach (Femenía-Font et al, 2006a) the enhancers PEG 600 and Transcutol ® were added in the formulation based on PVA, and the effect of occlusion was tested by means of covering the films with parafilm…”

Section: Introductionmentioning

confidence: 99%